Related Experiment Video
Updated: May 29, 2026
09:54
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Dopamine release in the basal ganglia
M E Rice1, J C Patel, S J Cragg
1Department of Neurosurgery, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. margaret.rice@nyu.edu
Neuroscience
|September 24, 2011
Summary
Dopamine (DA) signaling in the basal ganglia deviates from classic synaptic models. Local factors and DA neuron activity patterns intricately shape DA transmission, influencing movement disorders.
Area of Science:
- Neuroscience
- Neurochemistry
- Cellular Biology
Background:
- Dopamine (DA) is a crucial neurotransmitter in the basal ganglia.
- DA transmission exhibits unique characteristics that challenge the classic synaptic doctrine.
Purpose of the Study:
- To review and synthesize current understanding of dopamine signaling in the basal ganglia.
- To explore how DA release mechanisms and regulation differ from traditional synaptic transmission.
Main Methods:
- Review of existing literature on dopamine transmission in the basal ganglia.
- Analysis of findings from in vivo and in vitro mechanistic studies using voltammetry.
- Examination of anatomical and physiological evidence for DA release and receptor/transporter localization.
Main Results:
- Dopamine release occurs via vesicular exocytosis, influenced by action potentials and calcium.
- Somatodendritic DA release from midbrain neurons and extrasynaptic signaling in the striatum are observed.
- Local regulatory factors and the interplay of DA input timing with other neurotransmitters sculpt DA signaling.
Conclusions:
- Dopamine signaling in the basal ganglia is a complex process, not fully explained by the classic synaptic doctrine.
- Understanding these unique mechanisms is vital for insights into Parkinson's disease and other movement disorders.
- DA transmission is dynamically regulated by both intrinsic neuronal activity and local microenvironmental factors.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:27Diencephalon: Thalamus and Information Relay
The thalamus, often called “the gateway to the cerebral cortex,” is vital in processing and directing sensory and motor signals throughout the brain. Almost all inputs destined for the cerebral cortex, except for olfactory signals, are relayed through the thalamus. The thalamus is a sophisticated relay station, channeling information from various brain regions to the cerebral cortex, as well as a filter, prioritizing certain signals over others based on current physiological states or needs.
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...